FDA approves Reata's rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments

Indonesia Berita Berita

FDA approves Reata's rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 97%

FDA approves Reata’s rare nervous-system drug amid questions about changing regulatory environment for neuroscience treatments

The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.’s treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system.The drug, omaveloxolone, which is now called Skyclarys,... The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.’s treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system.

The approval comes one day after the departure of Billy Dunn, the FDA’s head of neuroscience. The announcement, which was confirmed by the FDA, moved the stocks of several companies with neurology drugs under review at the FDA on Monday. It also caught the attention of Wall Street analysts, who largely view Dunn’s exit from the FDA as a loss for the industry.

A congressional report released in December that assessed Aduhelm’s approval process said Dunn met with Alfred Sandrock, then the head of Biogen’s research and development, to discuss the failed clinical trials for Aduhelm. “Documents obtained from FDA show that following the meeting in Philadelphia, Biogen re-engaged in conversations with the agency,” the report stated.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

MarketWatch /  🏆 3. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

FDA neurosciences chief Billy Dunn to leave immediately, analysts raise concernFDA neurosciences chief Billy Dunn to leave immediately, analysts raise concernThe U.S. Food and Drug Administration neurosciences head Billy Dunn will retire from his role effective immediately, the health regulator told Reuters on Tuesday.
Baca lebih lajut »

'Scream VI' Experience Reveals Gale's New Book, Billy's Mask, and Other Easter Eggs'Scream VI' Experience Reveals Gale's New Book, Billy's Mask, and Other Easter EggsThe ScreamVI experience revealed Gale Weather's new book and confirmed who that cracked Ghostface mask belonged to!
Baca lebih lajut »

DeMar DeRozan, Zach LaVine combine for 56, Bulls zoom past WizardsDeMar DeRozan, Zach LaVine combine for 56, Bulls zoom past Wizards'We have to find ugly ways to win games,' Bulls coach Billy Donovan said.
Baca lebih lajut »

Bluegrasser Billy Strings Completes Trifecta of Nashville Shows With Ryman Auditorium HomecomingBluegrasser Billy Strings Completes Trifecta of Nashville Shows With Ryman Auditorium HomecomingStrings held court on the same hallowed stage that birthed bluegrass, as an artist both revitalizing the genre and taking it to greater heights.
Baca lebih lajut »

Young Sheldon May Have Explained Sheldon’s Worst Big Bang Theory LieYoung Sheldon May Have Explained Sheldon’s Worst Big Bang Theory LieSheldon supposedly told many lies about his childhood in The Big Bang Theory, and Young Sheldon season 6 may have explained the worst of them all.
Baca lebih lajut »

FDA authorizes first at-home joint flu, COVID-19 testFDA authorizes first at-home joint flu, COVID-19 testThe Food and Drug Administration has issued an emergency use authorization for the first over-the-counter at-home test than can detect whether someone has the flu or COVID-19.
Baca lebih lajut »



Render Time: 2025-03-10 16:42:10